The Experts below are selected from a list of 33 Experts worldwide ranked by ideXlab platform
Jan Tore Gran - One of the best experts on this subject based on the ideXlab platform.
-
the prevalence and incidence of mixed connective tissue disease a national multicentre survey of norwegian patients
Annals of the Rheumatic Diseases, 2011Co-Authors: Ragnar Gunnarsson, Oyvind Molberg, Ingemargrethe Gilboe, Jan Tore GranAbstract:Objectives Mixed connective tissue disease (MCTD) is an immune-mediated, systemic disorder of unknown aetiology. As the epidemiology of the disease is largely unknown, the authors performed a nationwide cross-sectional retrospective study to assess the prevalence and incidence of MCTD in Norway. Methods Every adult patient (≥18 years) with MCTD seen at one of the departments of rheumatology was reviewed for inclusion. Only patients who satisfied the following four criteria were included: clinical diagnosis of MCTD verified by a rheumatologist; positive serum anti-Ribonucleoprotein Antibody test; fulfilment of at least one of three of following criteria sets: the modified Sharp9s criteria, the criteria of Alarcon-Segovia and Villareal and those of Kasukawa; and exclusion of other connective tissue diseases. Results The four inclusion criteria were fulfilled by 147 adult Caucasian patients. The female to male ratio was 3.3 and the mean age at diagnosis of adult-onset MCTD was 37.9 years (95% CI 35.3 to 40.4 years). At the end of 2008, the point prevalence of living adult MCTD patients in Norway was 3.8 (95% CI 3.2 to 4.4) per 100 000 adults. The incidence of adult-onset MCTD in Norway during the period from 1996 to 2005 was 2.1 (95% CI 1.7 to 2.5) per million per year. Conclusions MCTD has a female predominance and the incidence and prevalence of MCTD is low, and lower than reported figures for polymyositis, dermatomyositis, systemic sclerosis and systemic lupus erythematosus. The prevalence estimates were similar across the three criteria sets of MCTD.
Carlo Selmi - One of the best experts on this subject based on the ideXlab platform.
-
sat0267 serum anti heterogeneous nuclear Ribonucleoprotein Antibody characterizes systemic sclerosis with anti centromere Antibody and severe raynaud s phenomenon with digital ulcers
Annals of the Rheumatic Diseases, 2019Co-Authors: Natasa Isailovic, Angela Ceribelli, Carolina Gorlino, Elena Generali, Maria De Santis, Marta Caprioli, Giacomo Maria Guidelli, Piercarlo Sarziputtini, Minoru Satoh, Carlo SelmiAbstract:Background: Systemic Sclerosis (SSc) is characterized by the presence of serum autoantibodies (autoAbs) which may be crucial in the diagnosis, prediction of organ involvement, follow-up, and treatment choices. However, SSc sera can be negative for autoAbs identified using commercially available tests, and several new and rare autoAbs have been identified in the last decade with immunoprecipitation (IP) techniques. We recently reported a new IP pattern corresponding to anti-heterogeneous nuclar Ribonucleoprotein (hnRNP) antibodies in a cohort of SSc patients. Objectives: To analyze the IP pattern of anti-hnRNP antibodies in SSc sera and determine their clinical and laboratory correlations. Methods: We investigated sera from 63 consecutive patients with SSc attending our Unit between 2014 and 2018, using protein-IP of 35S-methionine-labeled K562 cell extract followed by SDS-PAGE and autoradiography, and IP-Western Blot for hnRNP-L and C1+C2 following established protocols. Clinical charts were used to analyze clinical and laboratory data for possible statistical correlations, performed by Prism (GraphPad Software 4.0, Fisher exact test) with statistical significance set at p values Results: We identified a new protein-IP pattern characterized by a set of several proteins of 140/40-25kD in 8/63 (13%) SSc sera (Figure panel A). This IP pattern corresponds to the hnRNP complex which is composed of several proteins and RNAs involved in RNA processing and splicing. These proteins have molecular weights ranging between 32 and 45kD as the set of proteins we identified in our experiments. To define the 140/40-25kD pattern identified in 8 SSc cases, we performed IP-WB using two anti-hnRNP antibodies selected by the molecular weight of the target antigen. We tested anti-hnRNP C1+C2 and anti-hnRNP L monoclonal antibodies in these 8 samples after preparation by crosslinking of IgG to PAS beads and protein-IP protocol, followed by WB (Figure panel B). Results show that 5/8 SSc anti-140/40-25kD samples are positive for hnRNP L, while no reactivity was observed with hnRNP C1+C2 monoclonal Antibody. We further observed that anti- hnRNP antibodies are significantly associated with serum ACApositivity (p=0.008), severe Raynaud’s phenomenon with digital ulcers requiring IV prostacyclin (75%, 6/8 vs 7/54 ACA+, 13%; p=0.0006), and esophageal involvement in 4 cases. Conclusion: We identified anti-hnRNP antibodies as new target antigen of a subset of SSc patients with ACA positivity and severe peripheral vascular involvement. Additional analysis is necessary to study the several components of anti-hnRNP antibodies, and longitudinal data will provide evidence on the predictive value of this biomarker. Reference [1] Ceribelli A, et al. J Rheumatol. 2010 Oct;37(10):2071-5 Disclosure of Interests: Natasa Isailovic: None declared, Angela Ceribelli: None declared, Carolina Gorlino: None declared, Elena Generali: None declared, Maria De Santis: None declared, Marta Caprioli: None declared, Giacomo Maria Guidelli: None declared, Piercarlo Sarzi-Puttini: None declared, Minoru Satoh: None declared, Carlo Selmi Grant/research support from: AbbVie, Janssen, MSD, Novartis, Pfizer, Consultant for: AbbVie, Alfa-Sigma, Biogen, Bristol-Myrs Squibb, Celgene, Eli-Lilly, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Speakers bureau: AbbVie, Alfa-Sigma, Biogen, Bristol-Myrs Squibb, Celgene, Eli-Lilly, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB
Ragnar Gunnarsson - One of the best experts on this subject based on the ideXlab platform.
-
the prevalence and incidence of mixed connective tissue disease a national multicentre survey of norwegian patients
Annals of the Rheumatic Diseases, 2011Co-Authors: Ragnar Gunnarsson, Oyvind Molberg, Ingemargrethe Gilboe, Jan Tore GranAbstract:Objectives Mixed connective tissue disease (MCTD) is an immune-mediated, systemic disorder of unknown aetiology. As the epidemiology of the disease is largely unknown, the authors performed a nationwide cross-sectional retrospective study to assess the prevalence and incidence of MCTD in Norway. Methods Every adult patient (≥18 years) with MCTD seen at one of the departments of rheumatology was reviewed for inclusion. Only patients who satisfied the following four criteria were included: clinical diagnosis of MCTD verified by a rheumatologist; positive serum anti-Ribonucleoprotein Antibody test; fulfilment of at least one of three of following criteria sets: the modified Sharp9s criteria, the criteria of Alarcon-Segovia and Villareal and those of Kasukawa; and exclusion of other connective tissue diseases. Results The four inclusion criteria were fulfilled by 147 adult Caucasian patients. The female to male ratio was 3.3 and the mean age at diagnosis of adult-onset MCTD was 37.9 years (95% CI 35.3 to 40.4 years). At the end of 2008, the point prevalence of living adult MCTD patients in Norway was 3.8 (95% CI 3.2 to 4.4) per 100 000 adults. The incidence of adult-onset MCTD in Norway during the period from 1996 to 2005 was 2.1 (95% CI 1.7 to 2.5) per million per year. Conclusions MCTD has a female predominance and the incidence and prevalence of MCTD is low, and lower than reported figures for polymyositis, dermatomyositis, systemic sclerosis and systemic lupus erythematosus. The prevalence estimates were similar across the three criteria sets of MCTD.
Hidetoshi Inoko - One of the best experts on this subject based on the ideXlab platform.
-
major histocompatibility complex class ii gene associations with anti u1 small nuclear Ribonucleoprotein Antibody relationship to immunoreactivity with individual constituent proteins
Arthritis & Rheumatism, 1995Co-Authors: Masataka Kuwana, Yutaka Okano, Junichi Kaburaki, Kimiyoshi Tsuji, Hidetoshi InokoAbstract:Objective. To better define immunogenetic associations with the anti–U1 Ribonucleoprotein (U1 RNP) autoAntibody response. Methods. HLA class II alleles were determined by genotyping in 49 Japanese rheumatic disease patients with anti–U1 RNP Antibody and 43 race-matched healthy controls. Immunoreactivities to U1 RNP constituent proteins (70K, A, B/B′, and C) were detected by immunoblots using purified HeLa cell Sm antigen, and Antibody titer was determined by passive hemagglutination assay. Results. DQB1*0302 was significantly more frequent in anti–U1 RNP–positive patients than in controls (43% versus 14%; odds ratio [OR] = 4.6, corrected P = 0.03). All anti–U1 RNP–positive patients had either a DQB1*0601, *0602, *0301, *0302, or *0303 allele, which share tyrosine at position 30, and the amino acid sequence Thr, Arg, Ala, Glu, Leu, Asp, and Thr at positions 71–77 in the DQB1 s1 domain. In contrast, one of these alleles was found in 81% of the controls (OR = 24, P = 0.002). In addition, anti–U1 RNP Antibody was associated with unique DQB*0302; DRB1*0401 haplotype. Anti-70K reactivity and Antibody titer were positively associated with a basic amino acid residue, arginine or histidine, at position 13 (DR2 or DR4) and were negatively associated with the amino acid sequence Ile, Leu, Glu, and Asp at positions 67–70, which was present in some of the DR5-, DR6-, and DR8-associated alleles, in the DRB1 s1 domain. Anti-C reactivity was strongly associated with DR2, particularly with DRB1*1502. Conclusion. The several shared epitopes located on HLA–DRB1 and DQB1 genes control the anti–U1 RNP autoAntibody response.
Oyvind Molberg - One of the best experts on this subject based on the ideXlab platform.
-
the prevalence and incidence of mixed connective tissue disease a national multicentre survey of norwegian patients
Annals of the Rheumatic Diseases, 2011Co-Authors: Ragnar Gunnarsson, Oyvind Molberg, Ingemargrethe Gilboe, Jan Tore GranAbstract:Objectives Mixed connective tissue disease (MCTD) is an immune-mediated, systemic disorder of unknown aetiology. As the epidemiology of the disease is largely unknown, the authors performed a nationwide cross-sectional retrospective study to assess the prevalence and incidence of MCTD in Norway. Methods Every adult patient (≥18 years) with MCTD seen at one of the departments of rheumatology was reviewed for inclusion. Only patients who satisfied the following four criteria were included: clinical diagnosis of MCTD verified by a rheumatologist; positive serum anti-Ribonucleoprotein Antibody test; fulfilment of at least one of three of following criteria sets: the modified Sharp9s criteria, the criteria of Alarcon-Segovia and Villareal and those of Kasukawa; and exclusion of other connective tissue diseases. Results The four inclusion criteria were fulfilled by 147 adult Caucasian patients. The female to male ratio was 3.3 and the mean age at diagnosis of adult-onset MCTD was 37.9 years (95% CI 35.3 to 40.4 years). At the end of 2008, the point prevalence of living adult MCTD patients in Norway was 3.8 (95% CI 3.2 to 4.4) per 100 000 adults. The incidence of adult-onset MCTD in Norway during the period from 1996 to 2005 was 2.1 (95% CI 1.7 to 2.5) per million per year. Conclusions MCTD has a female predominance and the incidence and prevalence of MCTD is low, and lower than reported figures for polymyositis, dermatomyositis, systemic sclerosis and systemic lupus erythematosus. The prevalence estimates were similar across the three criteria sets of MCTD.
